Enveda Biosciences
Enveda Biosciences Raises $130M Series C
Quick Facts
Enveda Biosciences Raises $130M Series C
Biotechnology company using AI and metabolomics to discover new drugs from natural products and medicinal plants
Key Highlights
- Funding Amount: $130M Series C
- Valuation: Undisclosed
- Headquarters: Boulder, CO
- Founded: 2019
- Employees: 80-150
- Total Raised: $175M
About the Funding Round
Enveda Biosciences has successfully closed $130M Series C in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.
Investor Syndicate
The round was backed by a prestigious group of investors:
- FPV Ventures
- Kinnevik
- Lux Capital
This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Enveda Biosciences achieve its ambitious goals.
Market Opportunity
The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Enveda Biosciences's unique approach and proven technology position it well to capture significant market share in the coming years.
Company Background
Founded in 2019 and headquartered in Boulder, CO, Enveda Biosciences has established itself as an innovative player in the biotech space. With 80-150 employees, the company has built a strong team focused on delivering exceptional value to customers.
Next Steps
With this new funding, Enveda Biosciences plans to:
- Accelerate product development and innovation
- Expand into new markets and geographies
- Grow the team across engineering, sales, and operations
- Strengthen partnerships with key industry players
- Scale infrastructure to support rapid growth
Industry Impact
This funding round represents a strong vote of confidence in Enveda Biosciences's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.
For more information about Enveda Biosciences, visit their website or contact their press office.
Key Investors
About the Author
Related Company Reports
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza